|1.||Lee, Hyeong-Kyu: 1 article (04/2012)|
|2.||Jang, Ha-Young: 1 article (04/2012)|
|3.||Park, Mi-Jeong: 1 article (04/2012)|
|4.||Oh, Sei-Ryang: 1 article (04/2012)|
|5.||Kwon, Ok-Kyoung: 1 article (04/2012)|
|6.||Ahn, Kyung-Seop: 1 article (04/2012)|
04/01/2012 - "Administration of skullcapflavone II significantly reduced airway hyperresponsiveness (AHR), airway eosinophilia, Th2 cytokine production, and increased transforming growth factor-β1 (TGF-β1) levels in bronchoalveolarlavage (BAL) fluids and lungs from OVA-sensitized and -challenged mice. "
|4.||Asthma (Bronchial Asthma)
04/01/2012 - "Thus, skullcapflavone II may have therapeutic potential for the treatment of allergic asthma."
04/01/2012 - "Collectively, these findings indicate that skullcapflavone II, a potential bradykinin antagonist, reduced the major pathophysiological features of allergic asthma, at least in part by acting on TGF-β1/Smad signaling pathways. "
04/01/2012 - "Skullcapflavone II inhibits ovalbumin-induced airway inflammation in a mouse model of asthma."